Compare Angi Inc (ANGI) vs ClearPoint Neuro Inc (CLPT) Price & Performance

ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.

The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.

ClearPoint Neuro (CLPT) trades at $14.56, down slightly by 0.07% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth to $42 million but missed earnings estimates with a loss of $0.38 per share, reflecting ongoing investment in clinical and preclinical services. Despite negative net income margins and cash flow challenges, analyst consensus remains unanimously bullish with 3 buy ratings.

The outlook hinges on successful execution of growth initiatives in neuro drug delivery and regulatory progress with partners, though high valuation multiples and persistent losses pose significant risks. Near-term catalysts include Q3 2026 earnings and partner developments, but investors face volatility from operational cash burn and competitive pressures.